AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
17/10/2024 – AB Science today announces that the European Medicines Agency (EMA) confirmed a negative opinion for the conditional marketing authorization of masitinib in the treatment of amyotrophic lateral sclerosis